# Nuclide record nct07611110 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct07611110/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct07611110", "NCT07611110" ;
  schema:name "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)"@en ;
  schema:alternateName "VECTRA-01"@en ;
  schema:description "A phase 3 trial of FPI-2265, Cabazitaxel, Abiraterone acetate in prostate cancer, run by AstraZeneca, now recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct07611110/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07611110> ;
  nuclide:status "recruiting" ;
  nuclide:tag "ctgov-ingest" ;
  nuclide:phase "3" ;
  nuclide:related <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:drugs <https://nuclide.cc/drugs/fpi-2265/>, <https://nuclide.cc/drugs/cabazitaxel/>, <https://nuclide.cc/drugs/abiraterone/>, <https://nuclide.cc/drugs/enzalutamide/> ;
  nuclide:companies <https://nuclide.cc/companies/astrazeneca/> .